Which Beta-Blocker Is Best for Atrial Fibrillation?

No single beta-blocker has been proven clearly superior for atrial fibrillation across all patients. Guidelines from major cardiology societies recommend beta-blockers as a class for rate control but stop short of naming a preferred agent, largely because head-to-head trials comparing individual drugs remain scarce. The choice hinges on your other health conditions, how you metabolize the drug, and whether you need rate control at rest, during exercise, or both.

Why Guidelines Do Not Name a Winner

Canadian, European, and American atrial fibrillation guidelines all list beta-blockers alongside certain calcium channel blockers as first-line rate-control therapy for most patients who do not have heart failure or a recent heart attack.¹ Yet none of these guidelines single out one beta-blocker over another. The reason is straightforward: the agents differ in how tightly they target the heart’s beta-1 receptors, how long they last in your bloodstream, whether they dissolve in fat or water, and whether they carry extra properties like blood-vessel relaxation. Meanwhile, atrial fibrillation itself varies from person to person in how much it is driven by adrenaline surges, how structurally remodeled the heart is, and what other organs are affected.² Large randomized trials directly comparing one beta-blocker against another in atrial fibrillation simply have not been done, so guidelines default to recommending the class rather than a specific member.³

Metoprolol as the Common Starting Point

In everyday practice, metoprolol is the beta-blocker most often prescribed for atrial fibrillation. It is beta-1 selective, meaning it preferentially slows the heart without strongly affecting the lungs or blood vessels. It is available in two formulations that matter more than many patients realize: metoprolol tartrate, an immediate-release tablet typically taken two or three times a day, and metoprolol succinate, an extended-release tablet taken once daily.

A comparative study found that oral metoprolol succinate achieved the highest overall efficacy at roughly 78%, versus about 65% for oral tartrate, with the succinate group showing the largest drop in both heart rate and blood pressure.⁴ The steady plasma levels from the extended-release design likely explain the advantage: succinate delivers a smoother drug concentration over 24 hours, which avoids the peaks and valleys that come with dosing tartrate multiple times a day. That smoother profile also makes it easier for patients to stick with the medication.⁵ If you have been prescribed the short-acting version and find your heart rate creeps up before your next dose, switching to the extended-release form is a reasonable conversation to have with your doctor.

When Heart Failure Changes the Equation

Atrial fibrillation and heart failure frequently coexist, and the overlap changes which beta-blocker makes the most sense. Carvedilol is a non-selective beta-blocker that also blocks alpha-1 receptors, which relaxes blood vessels and lowers the workload on a weakened heart. In a retrospective analysis of U.S. heart failure trials, patients with atrial fibrillation who received carvedilol saw their heart’s pumping fraction improve from about 23% to 33%, compared with a much smaller gain on placebo. Physicians rated a greater proportion of carvedilol-treated patients as clinically improved, and there was a strong trend toward fewer deaths or heart-failure hospitalizations.⁶

That said, the picture is not entirely straightforward. A Japanese study found that the heart-rate-lowering effect of carvedilol may work differently in heart failure patients who are in atrial fibrillation versus those in normal rhythm, suggesting the benefit of slowing the rate may not translate equally across both groups.⁷ A substudy of patients with heart failure and coexisting atrial fibrillation found no significant interaction between beta-blocker use and the pattern of fibrillation (whether it came and went or was persistent) with respect to mortality or hospitalizations.⁸ The practical takeaway: if your heart is weakened, carvedilol has the strongest evidence base, but the benefit may depend on what your heart rhythm and pumping function look like as a package.

Digoxin is sometimes added to a beta-blocker in heart failure patients whose rate remains poorly controlled. By itself, digoxin does not improve survival, but pairing it with a beta-blocker can bring the average heart rate lower than either drug alone achieves.⁹ A crossover study comparing five rate-control regimens found that atenolol combined with digoxin produced the lowest 24-hour mean heart rate, around 65 beats per minute, substantially better than either drug used alone.¹⁰

Kidney Disease and the Clearance Problem

Your kidneys play a surprisingly large role in determining which beta-blocker is safe for you. Several commonly used agents, including atenolol and sotalol, are cleared primarily through the kidneys. When kidney function declines, these water-soluble drugs accumulate, raising the risk of excessive heart-rate lowering or other side effects.¹¹ Guidelines for managing atrial fibrillation in chronic kidney disease generally advise against atenolol and recommend lipophilic alternatives instead. Carvedilol, which is broken down almost entirely by the liver with minimal kidney involvement, typically does not need dose adjustment regardless of kidney function. Bisoprolol sits in between, with a mixed metabolism that may require tweaking as kidney function worsens.¹²

This is one area where the “default to metoprolol” approach works in the patient’s favor: metoprolol is metabolized by the liver via the CYP2D6 enzyme pathway, so declining kidney function does not cause it to pile up the way atenolol does. If you have been on atenolol for years and your kidney numbers start falling, a switch to metoprolol or carvedilol is a conversation worth having sooner rather than later.

Beta-Blockers and Lung Disease

For decades, doctors were taught to avoid all beta-blockers in patients with chronic obstructive pulmonary disease or asthma because blocking beta-2 receptors in the lungs can trigger airway tightening. The accumulated evidence tells a more nuanced story. Cardioselective beta-blockers, the ones that preferentially target beta-1 receptors on the heart and leave lung receptors mostly alone, are well tolerated in patients with COPD and do not appear to worsen breathing capacity or respiratory symptoms.¹³ In fact, some evidence suggests cardioselective beta-blockers may lower the risk of COPD flare-ups and reduce mortality.¹⁴

Despite that evidence, beta-blocker prescribing rates in COPD patients remain low. Many doctors still reflexively avoid them, and many patients are told they cannot take beta-blockers when in reality they can safely use a selective agent like metoprolol, bisoprolol, or nebivolol. If you have both atrial fibrillation and lung disease, the key distinction is selectivity: cardioselective agents are appropriate, while non-selective agents like carvedilol or propranolol carry more respiratory risk and are best avoided unless your heart failure specifically requires them.

Selective Versus Non-Selective in Acute Settings

When atrial fibrillation sends someone to the emergency department with a racing heart rate, intravenous beta-blockers are a common first move. A systematic review and meta-analysis of randomized trials examining IV beta-blockers for acute atrial fibrillation and flutter found no significant difference between beta-blockers and comparators in converting the rhythm back to normal, nor in rates of dangerously low heart rate, low blood pressure, or side effects severe enough to stop the drug. However, the incidence of both low blood pressure and excessive slowing was greater with non-selective beta-blockers than with selective ones.¹⁵ This makes intuitive sense: a drug that blocks receptors everywhere, including in the blood vessels, is more likely to drop blood pressure than one that focuses mainly on the heart. For emergency rate control, the safer bet is a beta-1-selective IV agent such as metoprolol or esmolol.

The Exercise Trade-Off

One complaint that comes up often with beta-blockers is exercise intolerance. Your heart rate during exertion is partly controlled by the same adrenergic system that beta-blockers dampen, so slowing the resting rate can also limit how fast the heart can respond during physical activity. A study in patients with chronic atrial fibrillation found that the beta-blocker celiprolol successfully reduced both resting and exercise heart rates. But oxygen uptake at peak exertion dropped by about 16%, and treadmill time fell by roughly 19%.¹⁶

That trade-off is inherent to the class, not unique to any one drug. The practical question is whether a drug with additional vasodilating properties can soften the blow. Nebivolol, a highly selective beta-1 blocker that also triggers nitric oxide release in blood vessels, has been reported to be as effective as metoprolol at preventing atrial fibrillation after cardiac surgery, and at a dose of 5 mg per day it achieved acceptable heart rate control in patients with chronic atrial fibrillation.¹⁷ The vasodilating effect may preserve exercise capacity better than a pure beta-blocker, though direct comparative exercise data in atrial fibrillation remain limited. If you are physically active and finding that your current beta-blocker leaves you winded during moderate exertion, nebivolol or carvedilol (which also has vasodilating properties through alpha blockade) may be worth discussing.

Sotalol Sits in a Different Category

Sotalol is technically a beta-blocker, but it occupies a unique niche because it also blocks potassium channels in the heart, giving it antiarrhythmic properties that other beta-blockers lack. That dual action means sotalol is sometimes used not just to control heart rate but to try to prevent atrial fibrillation episodes from recurring. A randomized trial in patients with a specific type of sick sinus syndrome who had pacemakers compared sotalol to standard beta-blockers and found no meaningful difference in preventing hospitalizations or the need for electrical cardioversion.¹⁸

The potassium-channel blocking effect comes with a risk that other beta-blockers do not carry: it can prolong a specific electrical interval in the heart (QT interval) and, rarely, trigger a dangerous arrhythmia. Sotalol therefore requires closer monitoring, including periodic electrocardiograms and kidney function checks, since it is renally cleared and accumulates when kidney function declines.¹¹ Sotalol is not interchangeable with a standard beta-blocker for simple rate control. It is reserved for rhythm management, and it requires more supervision.

Your Genes May Affect How You Respond to Metoprolol

Because metoprolol is the most commonly prescribed beta-blocker for atrial fibrillation, it is worth knowing that its breakdown in the body depends heavily on a liver enzyme called CYP2D6. People carry different genetic variants of the gene that encodes this enzyme, and those variants matter. A meta-analysis of 15 studies involving over 1,100 individuals found that people classified as poor metabolizers of CYP2D6 experienced a heart rate reduction about 3 beats per minute greater and a blood pressure drop about 3 mmHg greater than normal metabolizers on the same metoprolol dose. More concerning, poor metabolizers appeared to face roughly a fourfold higher incidence of excessive heart-rate slowing.¹⁹

About 5 to 10 percent of people of European descent are poor CYP2D6 metabolizers, meaning they break down metoprolol much more slowly and effectively experience a higher drug dose than intended. If you find that even a low dose of metoprolol leaves you dizzy, lightheaded, or with a resting heart rate in the 40s, your CYP2D6 status could be part of the explanation. Pharmacogenomic testing is increasingly available and can guide whether metoprolol is the right fit or whether a beta-blocker with a different metabolic pathway, such as atenolol (renally cleared) or carvedilol (metabolized by a different liver enzyme), would be a better match.

Timing and Circadian Rhythm

Heart rate in atrial fibrillation is not a flat line across the day. It follows a circadian rhythm, typically climbing during morning hours and dipping overnight. The crossover study of five rate-control regimens found that every treatment group showed a statistically significant circadian pattern in heart rate, meaning the 24-hour average only tells part of the story. Regimens that included atenolol shifted the time of peak heart rate later in the day, which may matter for patients whose symptoms are worst in the morning.¹⁰

This has practical implications. If you take your beta-blocker in the morning and notice that your heart races in the late afternoon or evening, the issue might be that the drug’s effect is wearing off before your next dose. Switching to an extended-release formulation, splitting a shorter-acting dose to cover more of the day, or timing the dose to align with your symptom peak can make a measurable difference in how well-controlled your rate feels during waking hours. Monitoring with a 24-hour heart rate recording rather than a single resting measurement in the clinic gives a far more useful picture of whether your regimen is actually working.

How to Think About the Choice

Since no trial has crowned a single best beta-blocker for atrial fibrillation, the decision tree is driven by what else is going on in your body. A quick map of the major branch points:

• No major comorbidities: Metoprolol succinate is the most common starting point, with once-daily dosing and a large safety track record.
• Heart failure with reduced pumping function: Carvedilol has the most favorable data for improving heart function and clinical outcomes in this overlap.
• Chronic kidney disease: Avoid atenolol and sotalol. Carvedilol requires no kidney-based dose adjustment; bisoprolol may need tweaking; metoprolol is liver-metabolized and generally safe.
• COPD or asthma: Stick with a cardioselective agent (metoprolol, bisoprolol, nebivolol). Avoid non-selective blockers like carvedilol or propranolol.
• Exercise intolerance is a priority: Consider nebivolol or carvedilol for their vasodilating properties, though expect some reduction in peak exercise capacity regardless of the specific drug.
• Suspected CYP2D6 poor metabolism: Pharmacogenomic testing can clarify. If confirmed, switch to a beta-blocker not dependent on that enzyme pathway.
• Rate still uncontrolled on a beta-blocker alone: Adding low-dose digoxin to the beta-blocker brings the 24-hour average rate lower than either drug alone.

These branch points overlap in real patients. Someone with heart failure and kidney disease might start on carvedilol. Someone with COPD and kidney disease might do well on metoprolol succinate. The choice is almost always a negotiation between the ideal drug for one condition and the safest drug across all of them.

When Rate Control Alone Is Not Enough

Standard beta-blockers control the ventricular rate during atrial fibrillation but do not restore normal rhythm. For some patients, particularly those with frequent, symptomatic episodes that disrupt quality of life despite adequate rate control, the goal shifts to rhythm management. Sotalol, as noted earlier, straddles both categories but comes with monitoring requirements that make it less convenient. More commonly, if rate control with a beta-blocker leaves you still feeling lousy, your doctor will look at dedicated antiarrhythmic drugs or catheter ablation rather than swapping to a different beta-blocker. The exception is the postoperative setting, where atrial fibrillation after cardiac surgery occurs in roughly a fifth to half of patients and beta-blockers including nebivolol are used both for rate control and prevention.¹⁷ Recognizing the boundary between rate control and rhythm control matters because cycling through beta-blockers endlessly is a less productive strategy than rethinking the treatment goal itself.